Background and Objectives: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer with a highly unfavorable prognosis. Aims: Retrospective statistical analysis of patients with HCC in the field of liver cirrhosis treated at our center from the perspective of demography, and the effects of key changes in diagnostic and therapeutic procedures in the last 10 years on overall survival (OS) and earlier diagnosis. Materials and Methods: This study included 170 cirrhotic patients with HCC (136 men, 80%). Demographic and etiological factors and OS were analyzed based on distribution into three groups according to the period and key changes in diagnostic and therapeutic approaches (BCLC classification staging; standardization of protocol for transarterial chemoembolization (TACE) and the introduction of direct-acting antivirals (DAA) for the treatment of chronic viral hepatitis C (HCV); expansion of systemic oncological therapy). Results: The mean age at the time of diagnosis was 69.3 years (SD = 8.1), and etiology was as follows: non-alcoholic steatohepatitis (NASH) 39%, alcoholic liver disease (ALD) 36%, HCV 18%, cryptogenic liver cirrhosis 3%, chronic hepatitis B infection (HBV) 2%, and other etiology 2%. Distribution of stages according to the BCLC: 0 + A 36%, B 31%, C 22%, and D 11%. However, the distribution in the first studied period was as follows: 0 + A 15%, B 34%, C 36%, and D 15%; and in the last period: 0 + A 45%, B 27%, C 17%, and D 11%, and difference was statistically significant (p < 0.05). The median OS for stages 0 + A, B, C, and D was 58, 19, 6, and 2 months, respectively. During the monitored period, there was a visible increase in the etiology of ALD from 30% to 47% and a decrease in HCV from 22% to 11%. In patients treated with TACE (stage B), the median OS grew from 10 to 24 months (p < 0.0001) between the marginal monitored periods. Conclusions: We described a decreasing number of patients with HCV-related HCC during follow-up possibly linked with the introduction of DAA. In our cohort, an improvement in early-stage diagnosis was found, which we mainly concluded as a result of proper ultrasound surveillance, the institution of a HCV treatment center, and increased experience of our sonographers with an examination of cirrhotic patients. Lastly, we described significantly improved overall survival in patients with intermediate HCC treated by TACE, due to the increased experience of interventional radiologists with the method at our facility and an earlier switch to systemic therapy in case of non-response to TACE.

Department of Internal Medicine 1st Faculty of Medicine Charles University and Military University Hospital Prague 169 02 Prague Czech Republic

Department of Internal Medicine Faculty of Military Health Sciences University of Defense 500 02 Hradec Kralove Czech Republic

Department of Radiodiagnostic Military University Hospital Prague 169 02 Prague Czech Republic

Zobrazit více v PubMed

Khalaf N., Ying J., Mittal S., Temple S., Kanwal F., Davila J., El-Serag H.B. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin. Gastroenterol. Hepatol. 2017;15:273–281.e1. doi: 10.1016/j.cgh.2016.07.033. PubMed DOI

Mazzaferro V., Bhoori S., Sposito C., Bongini M., Langer M., Miceli R., Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17:S44–S57. doi: 10.1002/lt.22365. PubMed DOI

Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 1999;19:329–338. doi: 10.1055/s-2007-1007122. PubMed DOI

European Association for the Study of The Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. PubMed DOI

Heimbach J.K., Kulik L.M., Finn R.S., Sirlin C.B., Abecassis M.M., Roberts L.R., Marrero J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380. doi: 10.1002/hep.29086. PubMed DOI

Marrero J.A., Kulik L.M., Sirlin C.B., Zhu A.X., Finn R.S., Abecassis M.M., Heimbach J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–750. doi: 10.1002/hep.29913. PubMed DOI

Bruha R. Doporučený postup pro léčbu a diagnostiku hepatocelulárního karcinomu. Gastroent. Hepatol. 2012;66:83–92.

Dong Y., Wang W.P., Lee W.J., Meloni M.F., Clevert D.A., Chammas M.C., Tannapfel A., Forgione A., Piscaglia F., Dietrich C.F. Hepatocellular carcinoma in the non-cirrhotic liver. Clin. Hemorheol. Microcirc. 2022;80:423–443. doi: 10.3233/CH-211309. PubMed DOI

Łapiński T., Tarasik A., Januszkiewicz M., Flisiak R. Clinical aspects and treatment of hepatocellular carcinoma in north- eastern Poland. Clin. Exp. Hepatol. 2021;7:79–84. doi: 10.5114/ceh.2021.104631. PubMed DOI PMC

White D.L., Thrift A.P., Kanwal F., Davila J., El-Serag H.B. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017;152:812–820.e5. doi: 10.1053/j.gastro.2016.11.020. PubMed DOI PMC

Dušek L. Epidemiologie Zhoubných Nádorů v České Republice. 2018. [(accessed on 2 May 2022)]. Available online: http://www.svod.cz.

Hung A.K., Guy J. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review. World J. Gastroenterol. 2015;21:12197–12210. doi: 10.3748/wjg.v21.i42.12197. PubMed DOI PMC

Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A.R., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978. doi: 10.1002/hep.23527. PubMed DOI

Li J., Zou B., Yeo Y.H., Feng Y., Xie X., Lee D.H., Nguyen M.H. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2019;4:389–398. doi: 10.1016/S2468-1253(19)30039-1. PubMed DOI

Kanwal F., Kramer J.R., Mapakshi S., Natarajan Y., Chayanupatkul M., Richardson P.A., El-Serag H.B. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018;155:1828–1837.e2. doi: 10.1053/j.gastro.2018.08.024. PubMed DOI PMC

Rabekova Z., Frankova S., Jirsa M., Neroldova M., Lunova M., Fabian O., Sperl J. Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk. Int. J. Mol. Sci. 2021;22:10560. doi: 10.3390/ijms221910560. PubMed DOI PMC

Liu Y.L., Patman G.L., Leathart J.B.S., Piguet A.C., Burt A.D., Dufour J.F., Anstee Q.M. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 2014;61:75–81. doi: 10.1016/j.jhep.2014.02.030. PubMed DOI

Dash S., Aydin Y., Widmer K.E., Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J. Hepatocell. Carcinoma. 2020;7:45–76. doi: 10.2147/JHC.S221187. PubMed DOI PMC

Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., Panel of Experts in HCC-Design Clinical Trials Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst. 2008;100:698–711. doi: 10.1093/jnci/djn134. PubMed DOI

Okusaka T., Kasugai H., Shioyama Y., Tanaka K., Kudo M., Saisho H., Sato T. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial. J. Hepatol. 2009;51:1030–1036. doi: 10.1016/j.jhep.2009.09.004. PubMed DOI

Meyer T., Fox R., Ma Y.T., Ross P.J., James M.W., Sturgess R., Palmer D.H. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): A randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 2017;2:565–575. doi: 10.1016/S2468-1253(17)30156-5. PubMed DOI

Chau I., Park J.O., Ryoo B.Y., Yen C.J., Poon R., Pastorelli D., Zhu A.X. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study. Br. J. Cancer. 2018;119:19–26. doi: 10.1038/s41416-018-0103-0. PubMed DOI PMC

Llovet J.M., De Baere T., Kulik L., Haber P.K., Greten T.F., Meyer T., Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2021;18:293–313. doi: 10.1038/s41575-020-00395-0. PubMed DOI

Lencioni R., de Baere T., Soulen M.C., Rilling W.S., Geschwind J.F.H. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016;64:106–116. doi: 10.1002/hep.28453. PubMed DOI

Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010;30:52–60. doi: 10.1055/s-0030-1247132. PubMed DOI